Ovarian Rejuvenation Therapy provided by Garavelas Athanasios
Ovarian rejuvenation is a procedure that can create new eggs in the ovaries of women who are unable to conceive due to early menopause, advanced maternal age or low ovarian reserve, but who wish to have their own biological child.
These individuals are able or not, according to their personal desires, to use the eggs of the donor or to adopt a child. New eggs do not develop in the ovaries under normal circumstances, and according to the current scientific understanding of ovarian physiology, a woman is born with all the eggs that will be available for conception during her reproductive life. Furthermore, it is a scientifically indisputable fact that the supply of a woman of eggs decreases in number and genetic quality as the age progresses.
The scientific basis of this clinical case of successful ovarian rejuvenation is most likely the following: the blood cells of patients, who were injected into the ovaries, have produced substances called growth factors, which the body produces normally in order to heal internal and external injuries. Among the many other important biological and immunological functions, growth factors cause the growth of new blood vessels, connective and nervous tissues by the activation of stem cells that are normally found in all parts of the human body. Stem cells can, under the correct biological stimulus, transform into any type of cell in the human body, including eggs. The presence of stem cells in the ovaries and their transformation into mature oocytes (egg cells) has been demonstrated in mice by Harvard researchers. Stem cells have also been shown to be present in human ovaries, so it is quite possible that they can be transformed into eggs by growth factors contained in their own white blood cells of individuals that were injected into the ovary. Growth factor injections, when used for many other types of medical treatments, consist of the patient's blood and blood cells and is called PRP (platelet-rich plasma) or PDGF (Platelet Derived Growth Factors).
Growth factors are naturally produced by some blood cells (platelets and white blood cells) when the body is injured in order to naturally repair the body's tissues. Remember in your childhood, "skinning" your knee and seeing a thick yellow substance form over the injured area? That was actually a combination of platelets, white blood cells, blood coagulation and growth factors that stop bleeding, prevent infection, and eventually cause new skin formation, blood vessels, connective tissues and nerves to replace those that were lost due to the injury.
PRP injections have been used clinically for many years by physicians for the treatment of soft tissue and connective tissue injuries, as well as in bone grafts. Many professional athletes use this therapy to accelerate the healing of their sports-related injuries. PRPs are also used in burned patients to help skin transplants and after cardiac surgery to aid healing of chest wall incisions.
The current clinical use of PRP is very broad from the treatment of ulcers to non-surgical facelifts. Of course there are research studies that both confirm and deny the effectiveness of PRP therapy in its multiple medical uses.
Nevertheless, its safety has not been questioned. Since it is made up of a person's blood, there can be no transmission via blood-borne viruses such as hepatitis or HIV, as has been reported with the use of other people's blood products. Furthermore, since there are no synthetic chemicals involved and the PRP therapy is done from its own blood products of the patients; the possibility of an allergic reaction is extremely unlikely.
The ovarian rejuvenation process involves two phases.
- The first step is the preparation of the patient’s PRP. This begins with the insertion of a needle into the vein to get several blood tubes. White globules and platelets are separated from red blood cells and serum by a procedure called centrifugation. PRP preparation takes less than an hour.
- The next part of the ovarian rejuvenation process is the injection of PRP into the ovaries. The main difference in our study and the technique described in the case study is that we use a non-surgical approach to ovarian injections.
In order to monitor whether the procedure has regenerated new eggs in the ovaries, AMH (anti-muller hormone), FSH, LH and estradiol levels are measured at monthly intervals for women who do not menstruate, and during menstrual flow for menstruating women, over a period of three months. If AMH levels increase, while FSH, LH, and estradiol levels become lower, there is evidence of objective evidence of ovarian rejuvenation.
Blood follow-up studies can be performed at our clinic or at a local blood sampling station. Participants are required to report the occurrence of spontaneous periods in menopausal women or the modification of menstrual patterns in those participants who have menstrual cycles. Any signs or evidence that pregnancy has occurred should be reported immediately.
For those women living overseas, we will provide instructions and advice on follow-up, monitoring of pregnancy and care. It is important to remember that any therapeutic effect of growth factors may require 3-6 months to be observed, since any type of tissue transformation will not be immediately apparent. Although ovarian rejuvenation is observed, pregnancy may not necessarily occur, as there may be other factors that could interfere with natural conception. Furthermore, the evidence of ovarian rejuvenation occurs, the patency of the tubes should be confirmed and the male partner must be re-evaluated with a sperm test and a post-coital test. If these tests show that natural conception is unlikely, we will advise the appropriate treatment.
Dr. Garavelas Athanasios is an Obstetrician Gynecologist Surgeon specialized in Reproductive Endocrinology and Assisted Reproduction. Dr. Garavelas currently maintains a private practice office in Athens, Rome and Milan.
Dr. Garavelas Athanasios was born in Athens and graduated from Medical School “La Sapienza” – Rome in 2004 and the following year he acquired his professional license. Since 2013, he holds the title of the medical specialty in “Obstetrics – Gynecology” from the Medical School of the University of Athens.
Dr. Garavelas holds two Master of Science Degrees in Reproductive – Regenerative Medicine and High Risk Pregnancy and a PhD in HPV and Chlamydia infections during Assisted Reproduction from the Medical School of the University of Athens. Moreover, he holds the title of specialized training in Human Reproduction of the University of Athens.
Dr. Garavelas currently maintains a private practice office in Athens, Rome and Milan.
Through his continuous work and practice, Dr. Garavelas has gained a significant experience in gynecological surgery and has executed an extensive number of interventions both gynecological and obstetrician. He is also trained in laparoscopic surgery, hysteroscopy, colposcopy, IVF, and, thoroughly, in the management of high-risk pregnancy cases.
Dr. Garavelas has presented his work in numerous Greek and International Conferences and has participated in several medical seminars and workshops, both in Greece and abroad. His work has been widely published in medical academic journals.
Presentation of scientific work in national conferences:
- Blunt hepatic injuries, surgical treatment: our experience. (4th Conference of the Hellenic Society of Trauma and Emergency Surgery, p. 136)
Presentations of scientific work in international conferences:
- Inguinal hernia repair using the Lichtenstein tension free hernioplasty (29th International Congress of the European Hernia Society p.24)
- Incisional hernia with great abdominal defect. Emergency repair using Gore-Tex dual mesh. Case report. (29th International Congress of the European Hernia Society P.25)
- Acute abdomen and intestinal obstruction due to incarcerated incisional hernia. (29th International Congress of the European Hernia Society p.68)
Dr. Garavelas is a registered member of the American Society of Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE).